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ABSTRACT
Resistance to targeted tyrosine kinase inhibitors (TKI) remains a challenge for 
the treatment of myeloid leukemias. Following treatment with TKIs, the bone marrow 
microenvironment has been found to harbor a small pool of surviving leukemic CD34+ 
progenitor cells. The long-term survival of these leukemic cells has been attributed, 
at least in part, to the protective effects of bone marrow stroma. We found that 
the NOX-A12 'Spiegelmer', an L-enantiomeric RNA oligonucleotide that inhibits  
SDF-1α, showed in vitro and in vivo activity against BCR-ABL- and FLT3-ITD-dependent 
leukemia cells. NOX-A12 was sufficient to suppress SDF-1-induced migration in 
vitro. The combination of NOX-A12 with TKIs reduced cell migration in the same 
in vitro model of SDF-1-induced chemotaxis to a greater extent than either drug 
alone, suggesting positive cooperativity as a result of the SDF-1 blocking function of 
NOX-A12 and cytotoxicity resulting from targeted oncogenic kinase inhibition. These 
results are consistent with our in vivo findings using a functional pre-clinical mouse 
model of chronic myeloid leukemia (CML), whereby we demonstrated the ability of 
NOX-A12, combined with the ABL kinase inhibitor, nilotinib, to reduce the leukemia 
burden in mice to a greater extent than either agent alone. Overall, the data support 
the idea of using SDF-1 inhibition in combination with targeted kinase inhibition to 
override drug resistance in oncogene-driven leukemia to significantly diminish or 
eradicate residual leukemic disease.
INTRODUCTION
CML is a malignancy of hematopoietic stem cells 
caused by the t(9;22) chromosome translocation product 
BCR-ABL [1]. Excessive proliferation and abnormal 
trafficking of transformed progenitor cells provides a 
survival advantage that is accompanied by premature 
release of these cells into the bloodstream of patients. This 
has been partially attributed to BCR-ABL-altered integrin 
expression or function affecting the communication 
between leukemic cells and the bone marrow stroma, as 
well as with important extracellular matrix proteins such 
as fibronectin [2–6]. Abnormal trafficking is also marked 
by the homing of malignant cells to bone marrow stroma 
and other tissue beds characterized by having high stromal 
cell content. This can lead to persistent minimal residual 
disease in CML patients undergoing therapy with targeted 
inhibitors such as imatinib and nilotinib, as stromal cells 
secrete growth factors and protect leukemia cells from 
targeted inhibitors [7]. Thus, in one study, CML recurred 
in more than 50% of patients who discontinued imatinib 
therapy after having achieved and maintained at least a 
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5-log reduction in BCR-ABL mRNA transcript levels, 
or a complete molecular response [8]. In a similar study 
where patients discontinued nilotinib, 51.6% of patients 
remained in remission 48 weeks after stopping treatment 
[9]. Residual BCR-ABL-positive leukemic stem cells in 
the bone marrow of TKI-treated patients with sustained 
undetectable molecular residual disease may lead to 
relapse following termination of TKI treatment [10]. 
Splenic stroma is also a source of soluble cytokines 
associated with hematopoiesis, and splenocytes provide 
viability signals that lead to growth and survival of 
leukemic cells [11–12]. Thus, in addition to bone marrow 
stroma, splenic stroma also can influence the viability and 
growth of malignant cells [13]. 
Early studies conducted by our group investigated 
the possibility that stromal cell-secreted cytokines 
might be able to confer cytoprotection to tyrosine kinase 
inhibitor-treated BCR-ABL-expressing cells. We found 
that a cytokine cocktail consisting of stromal-cell derived 
factor-1 (SDF-1 (or CXCL-12)), a bone marrow-secreted 
chemoattractant that supports stem cell homing, as well as 
a panel of cytokines secreted in high concentrations from 
human stromal cells, including interleukin (IL)-6, IL-8, 
IL-11, GM-CSF, and M-CSF [14], enhanced the growth 
of BCR-ABL-expressing cells and partially protected 
imatinib-treated leukemic cells [15]. Our findings are 
consistent with other published findings that demonstrated 
cytokine protection of chemotherapy-treated myeloid 
leukemia cells [16].
Clinical trial data show that the residual disease can 
persist in the bone marrow of patients with acute myeloid 
leukemia (AML) expressing oncogenic FLT3 that are 
treated with the small molecule inhibitor, midostaurin 
[17–20]. These findings suggest that, as with what has 
been observed for kinase inhibitor-treated CML, stromal 
cells similarly provide viability signals to AML cells that 
protect them from the effects of kinase inhibition. 
One approach to potentially override the 
cytoprotective effect of stroma on TKI-treated leukemic 
cells involves targeting the CXCR4 chemokine receptor 
and its ligand, SDF-1, which constitute a chemokine/
receptor axis that mediates hematopoietic cell migration 
to bone marrow stroma. CXCR4 antagonists direct 
leukemic cells away from cytoprotective stroma and 
thus have the potential to enhance the apoptosis-inducing 
effects of TKIs like imatinib [21]. Plerixafor (AMD3100; 
Mozobil™; Genzyme), an antagonist/partial agonist of 
CXCR4 and allosteric agonist of CXCR7 [22], is used 
clinically for harvesting hematopoietic stem cells for 
use in autologous transplantation in patients with non-
Hodgkin’s lymphoma and multiple myeloma (MM). We 
and others have shown that plerixafor potentiates the 
cytotoxic effects of chemotherapy- or TKIs- on stroma-
protected AML [23–25], MM [26–28], and CML [29–31]. 
Clinical trials investigating plerixafor and other agents 
targeting CXCR4, including anti-CXCR4 monoclonal 
antibodies and peptide CXCR4 antagonists, for leukemia 
and lymphoma are currently under way [32].
An alternative to inhibiting the CXCR4 receptor is 
targeting its ligand, SDF-1, directly. SDF-1 is secreted 
and presented by stromal cells from bone marrow and 
other tissues by cell-surface-bound glycosaminoglycans 
(GAGs); this attracts leukemia cells and contributes to 
residual disease by conferring protection to the cytotoxic 
effect of small molecule inhibitors. NOX-A12 is an RNA 
oligonucleotide in L-configuration (or the mirror image 
of naturally occurring RNA) (Spiegelmer), which makes 
it unrecognizable by plasma nucleases and resistant 
to degradation, and which was originally designed to 
interfere with SDF-1 in the stromal microenvironment 
[33–34]. NOX-A12 has been shown to inhibit SDF-1-
induced chemotaxis of chronic lymphocytic leukemia 
(CLL) cells and conversely augment migration of CLL 
cells beneath a bone marrow stromal cell (BMSC) layer 
by disrupting the BMSC-generated SDF-1 gradient [35]. 
It has also been found to reduce MM tumor burden in 
mice when combined with bortezomib [36], as well as to 
exhibit activity against glioblastoma in rat models [37] and 
potentiate anti-VEGF therapy against glioblastoma [38]. 
NOX-A12 was tested in healthy volunteers and found 
to be well-tolerated and to dose-dependently mobilize 
white blood cells and hematopoietic stem cells into the 
peripheral blood [39]. Thus far, encouraging results 
have been obtained in clinical trials testing NOX-A12 in 
combination with bendamustine and rituximab (BR) for 
the treatment of relapsed/refractory CLL patients, and 
testing of NOX-A12 in combination with bortezomib 
(Velcade) and dexamethasone (VD) in relapsed/refractory 
MM patients [40].
To date, to the best of our knowledge, therapeutic 
effects of NOX-A12 have not been explored in myeloid 
leukemia. Here, we show the ability of NOX-A12 to block 
SDF-1-induced migration of BCR-ABL-positive leukemia 
cells, as well as FLT3-ITD-positive leukemia cells. In 
addition, we demonstrate the combined effects of targeted 
kinase inhibition and NOX-A12 in vitro and in vivo.
RESULTS
NOX-A12 inhibits SDF-1-induced migration of 
BCR-ABL-expressing cells and potentiates the 
effects of ABL inhibition against BCR-ABL-
positive cells in vitro
In transwell migration assays designed to test the 
ability of NOX-A12 to inhibit SDF-1-induced migration 
of BCR-ABL-expressing cells, we found that 50–100 nM 
NOX-A12 effectively inhibited the SDF-1-stimulated 
migration of BCR-ABL-expressing Ba/F3 and 32D cells 
and reduced migration to a level similar to unstimulated 
control cells (Figure 1A, 1D and Supplementary 
Figure 1A). Specifically, SDF-1 induced migration of 
Oncotarget109975www.impactjournals.com/oncotarget
Ba/F3.p210 cells by 5–11.2 fold over control (Figure 
1A, 1D), whereas in the presence of NOX-A12 (50–100 
nM), SDF-1 only induced migration by 0.5–0.6 fold 
(Figure 1A, 1D). Similarly, SDF-1 induced migration 
of 32D.p210 cells by 23.1 fold, whereas in the presence 
of NOX-A12, SDF-1 only induced migration by 2 fold 
(Supplementary Figure 1A). Effects of SDF-1 observed 
in the transwell migration assay were confirmed to be due 
to effects on migration as opposed to increased growth of 
cells, as the proliferation of Ba/F3.p210 cells treated with 
SDF-1 for two days was found to be unchanged (Figure 
1B). Specifically, in contrast to the 11.2-fold induction 
of Ba/F3.p210 cell migration by SDF-1 (Figure 1A), we 
observed a mere 1.1-fold difference between untreated 
and SDF-1-stimulated Ba/F3.p210 cells with respect to 
proliferation. In addition, we showed in a separate set of 
studies performed in parallel that 19 hours of stimulation 
of Ba/F3.p210 cells with SDF-1 led to a strong induction 
of cell migration in a transwell migration assay, whereas 
19 hours of SDF-1 stimulation of Ba/F3.p210 cells did 
not lead to any measurable increase in cell proliferation 
(Supplementary Figure 1B–1C). We also tested (in 
parallel) the effects of NOX-A12 (50 nM) on proliferation 
as compared to migration, and we observed that while 
NOX-A12 strongly suppressed SDF-1-induced migration, 
it did not enhance or inhibit cell proliferation (Figure 1D–
1E). These data are in support of the effects of NOX-A12 
observed in the transwell migration assay being due to 
effects on migration as opposed to increased cell growth.
Importantly, NOX-A12 treatment combined with 
imatinib treatment of BCR-ABL-expressing cells resulted 
in reduced SDF-1-induced migration of cells as compared 
to NOX-A12 or imatinib alone, suggesting a positive 
combination effect of the two inhibitors in this in vitro 
assay when used together, likely due to direct inhibitory 
effects of NOX-A12 on SDF-1-induced cell migration 
coupled with cell cytotoxicity resulting from BCR-ABL 
kinase inhibition (Figure 1C). The difference between 
migration of control cells versus cells stimulated with 
SDF-1 was statistically significant (p < 0.001), and the 
differences between imatinib alone or NOX-A12 alone 
(each in the presence of SDF-1) and the combination 
of imatinib and NOX-A12 (in the presence of SDF-1) 
were statistically significant (p < 0.00005 and p < 0.05, 
respectively). The difference between migration for cells 
in the SDF-1 treatment group and migration for cells 
treated with imatinib+NOX-A12 in the presence of SDF-1 
was significant (p < 0.0005), and there was no statistically 
significant difference between migration of control cells 
and cells treated with NOX-A12 in the absence of SDF-1 
(p = 0.79). 
The anti-SDF-1 effect of NOX-A12 was not 
limited to murine cells, as evidenced by its ability to 
reduce, however not abolish, SDF-1-induced migration 
of the human BCR-ABL-positive acute lymphoblastic 
leukemia (ALL) line, SUP-B15, and the human FLT3-
ITD-positive line, MOLM14 (Figure 2). SUP-B15 cells, 
although not a myeloid line, is being used in our study 
as a representative human cell line model of Philadelphia 
chromosome-positive leukemia that is dependent on the 
BCR-ABL oncogene. Specifically, SDF-1 stimulation of 
SUP-B15 cells led to a 12.7-fold induction of migration 
of cells, whereas SDF-1 stimulation of SUP-B15 cells 
in the presence of NOX-A12 (10 nM) led to only a 4.7-
fold increase in cell migration, and in the presence of 
NOX-A12 (100 nM) led to only a 2.8-fold increase in cell 
migration (Figure 2A). 
NOX-A12 inhibits SDF-1-induced migration of 
FLT3-ITD-expressing cells and potentiates the 
effects of FLT3 inhibition against mutant FLT3-
positive cells
As stromal cell-mediated chemoresistance has 
proven to be a challenge for TKI-treated leukemia, and 
TKIs, such as midostaurin, are now in clinical use for 
mutant FLT3-positive leukemia, it was of interest to 
explore the clinical and cooperative potential of NOX-A12 
in the context of this disease. We first found that SDF-1 
stimulation of MOLM14 cells led to a 4.96-fold induction 
of migration of cells, whereas SDF-1 stimulation of 
MOLM14 cells in the presence of NOX-A12 (100 nM) led 
to a 0.82-fold induction of migration of cells (Figure 2B). 
We next observed that NOX-A12 effectively inhibited 
the SDF-1-stimulated migration of FLT3-ITD-expressing 
MOLM13-luc+ cells in a transwell migration assay and 
reduced migration to a level similar to unstimulated 
control cells (Supplementary Figure 2A). Specifically, 
SDF-1 stimulation led to migration of 5,125 cells, as 
compared to 1,375 migrated cells in the control, whereas 
SDF-1 stimulation in the presence of NOX-A12 (25 nM) 
led to migration of only 1,500 cells (Supplementary Figure 
2A). In addition, the combination of NOX-A12 (at 25 nM) 
and midostaurin led to slightly reduced SDF-1-induced 
migration of MOLM13-luc+ (813 cells) as compared to 
NOX-A12 alone (1,500 cells) or midostaurin alone (2,188 
cells) in the transwell migration assay (Supplementary 
Figure 2A). A similar combination study was carried 
out for MOLM14 cells (Figure 2B). As expected, we 
observed robust SDF-1 induction of cell migration, 
which was strongly suppressed by 25 nM NOX-A12. The 
combination of midostaurin and NOX-A12 (at 25 nM) 
similarly led to slightly greater suppression of MOLM14 
cell migration as compared to single agent-treated cells 
(Supplementary Figure 2B).
NOX-A12 potentiates the anti-proliferative 
effects of ABL inhibition against BCR-ABL-
positive cells in vivo
The simultaneous demonstrated anti-SDF-1 
influence of NOX-A12 coupled with cell killing by 
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TKI encouraged further studies exploring the ability of 
NOX-A12 to potentiate the effects of ABL inhibition 
in vivo, presumably by mobilizing BCR-ABL-positive 
leukemia cells out of bone marrow and into peripheral 
blood due to direct inhibition of SDF-1 and consequent 
blockade of its function in the stromal microenvironment 
as a chemoattractant. We utilized a mouse model of BCR-
ABL-positive leukemia to examine the in vivo effects of 
SDF-1 inhibition by NOX-A12 (40 mg/kg every other 
day administered subcutaneously (sc)), combined with 
the ABL inhibitor, nilotinib, administered by oral gavage. 
In a pilot study designed to determine the optimal dose 
of nilotinib to use in combination with NOX-A12, mice 
treated for four days with 30mg/kg nilotinib showed strong 
and rapid loss of leukemia burden, whereas NOX-A12 
alone did not inhibit in vivo leukemia growth (data not 
shown). As the effects of nilotinib were disproportionate 
to the effects of NOX-A12, the nilotinib dose was reduced 
Figure 1: NOX-A12 inhibition of SDF-1-induced migration of BCR-ABL-expressing Ba/F3 cells and potentiation 
of effects of ABL inhibition against BCR-ABL-positive Ba/F3 cells in vitro. (A) Transwell migration assay (n = 1); error 
bars (standard deviation) represent intra-experimental variability, with multiple quantifications taken for one Transwell migration assay. 
Ba/F3.p210 cells were stimulated with mSDF-1 (100 ng/mL) in the absence or presence of NOX-A12 (100 nM). Data are presented 
as fold migration/control, where control is normalized to a value of 1. Transwell migration assay incubation time was overnight for 
Ba/F3.p210 cells. Data shown are mean +/− S.D. (B) Effect of mSDF-1 (100 ng/mL) on proliferation of Ba/F3.p210 cells following 
approximately 2 days of treatment. (C) Transwell migration assay: Ba/F3.p210 cells stimulated with mSDF-1 (100 ng/mL) in the presence 
of 25 nM NOX-A12, 1000 nM imatinib, or a combination of both. Transwell migration assay incubation time was overnight to 24 hours. 
Results shown are a composite of 3–4 independent experiments and error bars (standard deviation) represent inter-experimental variability. 
Data shown are mean +/− S.D. 2-sided t-test, p values: Control versus SDF-1 is statistically significant (p = 0.00076). *SDF-1 versus 
SDF-1+imatinib+NoxA12 is statistically significant (p = 0.00032). *SDF-1+imatinib versus SDF-1+imatinib+NOX-A12 is statistically 
significant (p = 0.00003). *SDF-1+NOX-A12 versus SDF-1+imatinib+NOX-A12 is statistically significant (p = 0.01758). Control versus 
NOX-A12 in the absence of SDF-1 is not statistically significant (p = 0.79296). (D) Transwell migration assay (n = 1); error bars (standard 
deviation) represent intra-experimental variability, with multiple quantifications taken for one Transwell migration assay. Ba/F3.p210 cells 
were stimulated with mSDF-1 (100 ng/mL) in the absence or presence of NOX-A12 (50 nM). Data are presented as number of migrated 
cells. Transwell migration assay incubation time was 24 hr. Data shown are mean +/− S.D. (E) Effect of NOX-A12 (25–50 nM) on 
proliferation of Ba/F3.p210 cells following approximately 24 hr of treatment. Data are presented as cell concentration (cell number/mL). 
Data shown are mean +/− S.D.
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by 2-fold and mice were treated orally for a total of 11 
days with 15mg/kg nilotinib in the presence or absence 
of 40 mg/kg NOX-A12 every other day sc. Nilotinib-
treated mice were observed to carry very low leukemia 
burden following 15 days total treatment (Supplementary 
Figure 3A, 3B) as compared to vehicle-treated mice and 
NOX-A12 only-treated mice. However, the combination 
of NOX-A12 and nilotinib led to further suppression of 
leukemia growth in 2 of 3 mice in the combination group 
as compared to nilotinib only-treated mice (Supplementary 
Figure 3C).
The results of the pilot study encouraged us to 
test nilotinib at a lower dose (7.5 mg/kg every day 
administered by oral gavage) alone and in combination 
with NOX-A12 in BCR-ABL-positive leukemia-bearing 
mice. As expected, NOX-A12 showed no single-agent 
Figure 2: NOX-A12 inhibition of SDF-1-induced migration of BCR-ABL-expressing human SUP-B15 cells and 
FLT3-ITD-positive human MOLM14 cells. (A) Transwell migration assay (n = 1); error bars (standard deviation) represent intra-
experimental variability, with multiple quantifications taken for one Transwell migration assay. SUP-B15 cells were stimulated with hSDF-
1 (100 ng/mL) in the presence of NOX-A12 (1–100 nM). Data are presented as number of migrated cells. Transwell migration assay 
incubation time was 24 hours for SUP-B15. Data shown are mean +/− S.D. (B) Transwell migration assay (n = 1); error bars (standard 
deviation) represent intra-experimental variability, with multiple quantifications taken for one Transwell migration assay. MOLM14 cells 
were stimulated with hSDF-1 (50 ng/mL) in the presence of NOX-A12 (100 nM). Data are presented as fold migration/control, where 
control is normalized to a value of 1. Transwell migration assay incubation time was overnight. Data shown are mean +/− S.D. 
Oncotarget109978www.impactjournals.com/oncotarget
activity, however in combination with nilotinib it led to 
reduced total leukemia burden assessed by total body 
bioluminescence (Figure 3A–3C). Spleens dissected 
from vehicle- and drug-treated mice were significantly 
smaller in the drug combination group than in vehicle-
treated or single agent-treated mice (Figure 4). The size 
of spleens of NOX-A12-treated mice were significantly 
different from the spleen sizes of combination-treated 
mice (p = 0.02564), and the size of spleens of nilotinib-
treated mice were significantly different from the spleen 
sizes of combination mice (p = 0.03602). Drugs, alone and 
combined, were generally well-tolerated by mice with no 
adverse toxicity to vital organs (data not shown). Since 
NOX-A12 exerted no efficacy as a single agent, these 
results demonstrate that NOX-A12, at a well-tolerated 
dose, acts cooperatively with nilotinib to suppress the 
growth of 32D.p210 leukemia.
DISCUSSION
The important role of stroma in leukemia cell 
trafficking is evident from the number of studies that 
have been carried out over the past couple of decades. 
Abnormal adhesion properties are believed to interfere 
with stroma:leukemia cell interaction and lead to 
increased leukemic cell proliferation and the untimely 
Figure 3: NOX-A12 potentiation of effects of ABL inhibition against BCR-ABL-positive cells in vivo: Effects on total 
body leukemia burden. Mice were IV-injected via tail vein with 1 million 32D.p210-luc+ cells and imaged 3 days later to establish 
baseline bioluminescence. Mice were randomized into the following four treatment groups: Vehicles (administered NMP/PEG solution via 
oral gavage every day), NOX-A12-only (40 mg/kg sc every other day), nilotinib (7.5mg/kg oral gavage every day), or a combination. Mice 
were continuously administered treatments until morbidity. Mice were preserved in 10% formalin for histopathological analysis. (A–B) 
Fold leukemia induction (32D.p210-luc+ cells IV injected via tail vein) for treatment groups on treatment day 8 (A) and treatment day 15 
(B); “n” refers to the number of mice in each treatment group. Bioluminscence values for one NOX-A12-only mouse and one combination-
only mouse were too low to be considered reliable on day 15 of treatment and were therefore not included in determination of fold leukemia 
induction for treatment day 15 and treatment day 8 (for consistency). (C) Shown here are bioluminescent images for four representative 
mice prior to treatment (baseline) and on day 19 of treatment.
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release of these cells out of patient bone marrow and into 
the peripheral blood. The converse homing of leukemic 
cells to bone marrow stroma dampens the efficacy of TKI 
therapy because of cytoprotection of leukemic cells and 
consequent development of minimal residual disease. 
New approaches to overriding stromal cell-associated 
chemoresistance, such as the use of agents that inhibit the 
CXCR4-SDF-1 axis, could potentially improve leukemia 
patient response and survival if developed as anticancer 
therapeutics. Of relevance in the case of CML, while there 
is a reduction of CXCR4 expression and signaling in BCR-
ABL-positive cells, conversely treatment with imatinib or 
nilotinib increases CXCR4 surface expression on CML 
cells; this causes these cells to migrate to cytoprotective 
bone marrow stroma, rendering them resistant to TKI 
therapy [29, 41, 42]. 
NOX-A12 is an RNA oligonucleotide in 
L-configuration (Spiegelmer®) that binds and neutralizes 
SDF-1 thereby blocking its interaction with CXCR4 
and CXCR7 and which also disrupts existing SDF-
1 gradients by stripping the chemokine from GAGS 
[35]. By inhibiting SDF-1 with NOX-A12, the tumor 
microenvironment can be modulated in such a way as 
to mobilize leukemia cells to the peripheral blood where 
they are more susceptible to the cytotoxicity of anti-cancer 
agents. Additionally, as SDF-1 behaves as a survival factor 
for leukemic cells, blockade of SDF-1 could potentially 
reduce leukemia cell viability [40]. NOX-A12, because of 
its ability to block SDF-1 activity on both of its receptors, 
CXCR4 and CXCR7, provides additional benefit over 
a targeted CXCR4 receptor inhibitor because of its 
dual influence on CXCR7, which affects proliferation, 
migration, and metastasis of some cancers [43]. 
To the best of our knowledge, the activity of 
NOX-A12 alone and in combination with targeted 
therapies has not been explored for CML and AML. 
Here, we observed the ability of NOX-A12 to potentiate 
the effects of ABL inhibition against BCR-ABL-positive 
leukemia in vitro and in vivo. In transwell migration 
assays, NOX-A12 inhibited SDF-1-induced migration of 
BCR-ABL-expressing Ba/F3, 32D, and SUP-B15 (human 
Ph+ ALL) cells. NOX-A12 also potently inhibited SDF-
Figure 4: NOX-A12 potentiation of effects of ABL inhibition against BCR-ABL-positive cells in vivo: Effects on spleen 
weight. Percent spleen/total weights for treatment groups. *NOX-A12 versus combination statistically significant (p = 0.025643). *Nilotinib 
versus combination statistically significant (p = 0.036021). 
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1-induced migration of FLT3-ITD-expressing MOLM13 
and MOLM14 cells.
Using a murine model of BCR-ABL-positive 
progressive disease, we found that NOX-A12 combined 
with nilotinib was more effective in reducing leukemia 
burden than either drug alone. In our models, NOX-A12 
modestly enhanced the efficacy of nilotinib when nilotinib, 
as a single agent, was used at doses that led to substantial 
suppression of leukemia. However, a stronger positive 
combination effect was observed between NOX-A12 
and a lower dose of nilotinib that was ineffective when 
administered as monotherapy. As such, combination 
treatment may have a particularly effective role in those 
patients not able to tolerate TKI treatment and for whom 
dose reduction of the TKI is needed. 
Taken together, our data confirm the anti-SDF-1 
activity of the ‘Spiegelmer’ and L-enantiomeric RNA 
oligonucleotide, NOX-A12. Our findings also suggest that 
NOX-A12 has the ability to potentiate the efficacy of TKIs 
against a subset of oncogene-driven leukemias.
MATERIALS AND METHODS
Cell lines and cell culture
BCR-ABL tyrosine kinase-dependent murine 32D.
p210 cells were developed as described [44]. SUP-B15 
cells were purchased from the American Type Culture 
Collection (ATCC) (Manassas, VA, USA). Ba/F3.p210 
cells were obtained by transfecting the IL-3-dependent 
murine hematopoietic Ba/F3 cell line with a pGD vector 
containing p210BCR-ABL (B2A2) cDNA [45]. 
The human AML-derived, FLT3-ITD-expressing 
line, MOLM14, was provided to us by Dr. Scott 
Armstrong, Dana-Farber Cancer Institute (DFCI), Boston, 
MA. The human AML-derived, FLT3-ITD-expressing cell 
line, MOLM-13 (DSMZ (German Resource Centre for 
Biological Material), was engineered to express luciferase 
fused to neomycin phosphotransferase (pMMP-LucNeo) 
by transduction with a VSVG-pseudotyped retrovirus as 
previously described [46]. 
All cell lines used in this study were cultured with 
5% CO2 at 37
oC, at a concentration of 2 × 105 to 5 × 105 
in RPMI (Corning, Inc. Corning, NY) with 10% HyClone 
fetal bovine serum (FBS) (GE Healthcare Life Sciences, 
Pittsburgh, PA), and supplemented with 2% L-glutamine 
and 1% penicillin/streptomycin.
Human cell lines were authenticated through 
cell line short tandem repeat (STR) profiling (DDC 
Medical, Fairfield, OH and Molecular Diagnostics 
Laboratory, Dana-Farber Cancer Institute). All cell lines 
tested matched > 80% with lines listed in the ATCC or 
DSMZ Cell Line Bank STR. SUP-B15 cells were newly 
purchased from ATCC at the time of this study. All cell 
lines were confirmed to be virus- and mycoplasma-free. 
Chemicals
Midostaurin (Rydapt) and nilotinib (Tasigna) were 
synthesized by Novartis Pharma AG, Basel, Switzerland 
and dissolved in DMSO to obtain a 10 mM stock solution. 
Serial dilutions were then made, to obtain final dilutions 
for cellular assays with a final concentration of DMSO 
not exceeding 0.1%. Stock solutions of the RNA nucleic 
acid, NOX-A12/olaptesed pegol (Noxxon, Germany), 
were prepared in 5% glucose in water at a 5 mg/mL 
concentration and stored as aliquots, light-protected, at 
-20oC.
Proliferation studies
The trypan blue exclusion assay has been previously 
described [47] and was used for quantification of cells 
prior to seeding for CellTiter-Glo Luminescent Cell 
Viability assays (Promega, Madison, WI). These assays 
were used for cell growth studies and carried out according 
to manufacturer’s instructions. Cell viability is reported 
as percentage of control (untreated) cells, and error bars 
represent the standard deviation for each data point. 
Transwell migration assay
For murine Ba/F3.p210 and 32D.p210 cells, the 
lower chamber of a Transwell plate (6.5mm Transwell® 
with 5.0µm Pore Polycarbonate Membrane Insert, Sterile 
(Product #3421), Corning Costar Corporation, Cambridge, 
MA) was filled with 600 µL of migration (starvation) 
media (RPMI 1640/PBS+0.01% bovine serum albumin 
(BSA)), followed by placement of inserts into the wells. 
For human SUP-B15, MOLM13 and MOLM14 cells, the 
lower chamber of a Transwell plate (6.5mm Transwell® 
with 8.0µm Pore Polycarbonate Membrane Insert, Sterile 
(Product #3422), Corning Costar Corporation, Cambridge, 
MA) was filled with 600 µL of migration (starvation) 
media (IMDM/PBS+0.05% BSA) followed by placement 
of inserts into the wells. Cells were counted by Trypan 
Blue exclusion with a hemocytometer, and resuspended 
in migration media at a concentration of 2 × 106 cells/
mL. 100 µL of this cell suspension was transferred to the 
upper chamber (for a total of 2 × 105 cells). The media in 
the lower chamber contained either no SDF-1 (for control 
samples) or 100 ng/mL mouse SDF-1 (for Ba/F3.p210 
and 32D.p210 cells) or 50–100 ng/mL human SDF-1 (for 
MOLM13, MOLM14, or SUP-B15 cells). NOX-A12 and 
kinase inhibitors were included in the assay and added to 
the top and bottom chambers to avoid gradient formation 
at the indicated concentrations. After the indicated times, 
cells in the lower compartment were resuspended and 
counted using Trypan Blue exclusion. The spontaneous 
Transwell migration of cells was expressed as the total 
number of cells that migrated in the presence of SDF-1 
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versus SDF-1+NOX-A12. Shown are mean+/− S.D. for 
each sample.
Bioluminescent BCR-ABL model of CML 
32D.p210 cells were transduced with a retrovirus 
encoding firefly luciferase (MSCV-Luc), and selected with 
G418 at a concentration of 1 mg/mL to produce the 32D.
p210-luciferase (luc+) cell-line. Bioluminescence imaging 
was carried out as previously described [48]. Briefly, 
virus- and Mycoplasma-free cells were washed in Hank’s 
Balanced Salt Solution (HBSS; Mediatech, Inc.,VA), 
resuspended in PBS for injection, and administered via IV 
tail vein injection (250 µL, 1 × 106 cells) into 15 female 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (or NOD scid gamma 
(NSG™)) (6 weeks of age) (cat # 005557), purchased from 
The Jackson Laboratory (Bar Harbor, ME). Mice were 
imaged 3 days later to establish baseline bioluminescence 
and were randomized into the following four treatment 
groups: Vehicles (administered NMP/PEG solution), 
NOX-A12-only (40 mg/kg sc every other day), nilotinib 
(7.5 mg/kg oral gavage every day), or a combination. Mice 
were continuously administered treatments until morbidity, 
at which time spleens were dissected and weighed and 
reported as a percentage of total mouse weight. 
Drug formulations for in vivo studies
Solutions of nilotinib (Novartis Pharma AG, Basel) 
were prepared just prior to administration, by dissolving 
100 mg in 1.0 mL of NMP to give a clear solution and 
diluting with 9.0 mL PEG300. Working solutions of 
NOX-A12 were prepared by adding ca. 50% of target 
volume (e.g. 5 mL to 100 mg container) of 5% glucose 
in water and dissolving the lyophilisate under aseptic 
conditions. Incubation for at least 30 minutes at 37°C 
was required to completely dissolve the lyophilisate with 
occasional vortexing. The solution was rinsed two times 
with ca. 20% of the target volume of solution medium 
(e.g. 2 mL) and the rinsed solution was transferred to a 
preparation container. Solution medium was added to 
target volume (e.g. 10 mL). Aliquots prepared at 10 mg/
mL were stored, light protected, as stock solutions at 
−20°C and thawed prior to use. 
Statistical analysis
Results were reported as the mean ± standard 
deviation. Samples were compared by the Student’s t-test, 
and results were considered significantly different for p 
values less than 0.05.
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